Clinical Trial

0.005% Latanoprost Gel for Nonsegmental Vitiligo

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 11, 2025 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Latanoprost, a prostaglandin F2α (PGF2α) analog used for glaucoma treatment, is known to cause iris darkening, hypertrichosis, and periocular skin hyperpigmentation. PGF2α has been shown to stimulate the growth of melanocyte dendrites, increasing dendricity even at low doses, as well as enhancing tyrosinase activity and quantity, thereby promoting repigmentation. Studies on the use of 0.005% latanoprost gel in both children and adults with vitiligo have demonstrated effective repigmentation without reported side effects.
Trial Details
NCT Number NCT07016113
Lead Sponsor Universitas Padjadjaran
Conditions Vitiligo - Macular Depigmentation
Enrollment 10 participants
Start Date 2025-07-01
Primary Completion 2025-10-31 (estimated)
Study Completion 2025-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-11